RYTM News and Press, Rhythm Pharmaceuticals Inc. From 08/01/23

2023-08-01 10:04:48 ET Gainers: Adamis Pharmaceuticals ( ADMP ) +71% . ABVC BioPharma ( ABVC ) +49% . EQRx ( EQRX ) +18% . Rhythm Pharmaceuticals ( RYTM ) +17% . Esperion Therapeutics ( ESPR ) +6% . Losers: TG Therapeu...

2023-08-01 07:15:14 ET Rhythm Pharmaceuticals press release ( NASDAQ: RYTM ): Q2 GAAP EPS of -$0.82 misses by $0.04 . Revenue of $19.2M (+111.9% Y/Y) beats by $4.17M . For further details see: Rhythm Pharmaceuticals GAAP EPS of -$0.82 misses by $0.04, rev...

2023-08-01 07:14:08 ET Rhythm Pharmaceuticals press release ( NASDAQ: RYTM ): Q2 GAAP EPS of -$0.82 misses by $0.04 . Revenue of $19.22M (+112.1% Y/Y) beats by $4.19M . Net product revenues relating to global sales of IMCIVREE were $19.2 million for the second ...

-- Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE ® (setmelanotide) -- -- Strong U.S. commercial progress continues with more than 125 new prescriptions for Bardet-Biedl syndrome (BBS) in 2Q 2023, more than 425 since FDA approval -- ...

2023-07-31 14:51:15 ET Rhythm Pharmaceuticals ( NASDAQ: RYTM ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, before market open. The consensus EPS Estimate is -$0.78 (+12.4% Y/Y) and the consensus Revenue Estimate is $15.03M (+550.6% Y/Y). Over t...

BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwa...

BOSTON, July 17, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwa...

-- Mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean BMI reduction at 16 weeks -- -- Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity ongoing; completion of enrollment expected 1Q 2024 -- BOS...

2023-06-07 19:08:50 ET Summary Today, we check back in on Rhythm Pharmaceuticals, Inc., an entrant into the fast-growing weight management medicine space. The company is simultaneously trying ramp up sales from its franchise drug while advancing it in development for other indicat...

BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway dis...